Her group compared BRCA1/2 mutation carriers who chose RRBM versus those who preserved their breasts and concluded that, in women with a BRCA1 or BRCA2 pathogenic variant, RRBM reduced the risk of breast cancer (HR 0.20). Here, BRCA2 is linked to breast carcinoma.